Pine Bark Extract

Standardized French maritime pine bark extract — branded as Pycnogenol by Horphag — is the most-studied OPC-class polyphenol on the market, with replicated A-tier evidence in chronic venous insufficiency (Cochrane), allergic rhinitis, ADHD adjunct (Trebatická 2006), endothelial function / mild blood pressure (Liu 2013 meta-analysis), and erectile function (Stanislavov 2003). Mechanism: free-radical scavenging + endothelial NO upregulation + mild antiplatelet + anti-inflammatory + collagen support. Very safe (decades of human use, no major safety signals). Generic pine bark and grape seed extract share the OPC backbone and are 3-5× cheaper but quality is variable. For Dylan: OPTIONAL-ADD, low priority. The V4/V5 stack already runs a strong antioxidant/anti-inflammatory line (astaxanthin + curcumin + NAC + apigenin + fish oil). Pine bark would be a reasonable LATERAL add for vascular focus, allergic rhinitis, or ADHD support — not a primary pillar. If added: Pycnogenol 100-200 mg/day (split AM + lunch), Horphag-branded for batch quality, ~$25-40/mo.

Pine bark extract — and specifically Pycnogenol, the trademarked Horphag Research extract from Pinus pinaster (Pinus maritima) growing in the Les Landes de Gascogne forest in southwest France — is a standardized mixture of 65-75% procyanidins (oligomeric proanthocyanidins, OPCs) plus monomeric flavonoids (catechin, epicatechin, taxifolin / dihydroquercetin), phenolic acids (caffeic, ferulic, p-hydroxybenzoic, p-coumaric, gallic, vanillic), and small amounts of organic acids. The OPCs are dimers, trimers, and longer-chain oligomers of (+)-catechin and (-)-epicatechin units linked at C4-C8 or C4-C6 positions — the same monomer chemistry as grape seed, cocoa, and apple skin OPCs, but with a French-maritime-pine-specific procyanidin distribution.

Calling it "Pycnogenol" specifically refers to the Horphag-standardized product; "pine bark extract" generically can mean almost any Pinus species and any procyanidin profile. Most clinical trials (and almost all the A-tier evidence) used Pycnogenol; generics with similar OPC profiles (Oligopin from Pinus pinaster, Flavangenol Japanese-market equivalent) have less but credible clinical data.

Key mechanisms relevant to Dylan:

1. Free-radical scavenging — direct + indirect. OPCs and monomeric flavonoids quench superoxide, hydroxyl, peroxyl, and singlet oxygen radicals through their multi-hydroxyl polyphenolic structure. The often-quoted "4× the antioxidant capacity of vitamin C, 50× vitamin E" headline comes from in-vitro ORAC / DPPH assays at supraphysiological concentrations and overstates real-world plasma activity — but Pycnogenol does measurably raise plasma antioxidant capacity (TAC, ORAC) and lower MDA, oxidized LDL, and isoprostanes in many human trials. Mechanism layers with astaxanthin (membrane), curcumin (Nrf2 amplifier), NAC (GSH precursor), and vitamin C without overlap because pine bark's OPCs preferentially partition to plasma + vascular wall + skin, not deep into membrane bilayers.

2. Endothelial NO upregulation (the key vascular mechanism). Pycnogenol upregulates endothelial nitric oxide synthase (eNOS) expression and activity, increasing endothelium-derived NO production. This is the mechanism behind the flow-mediated dilation (FMD) improvements in Liu 2013's meta-analysis, the BP-lowering signal in hypertensive populations, the cold-extremity / Raynaud's-adjacent symptom improvements, and — crucially — the synergistic effect with L-arginine in the Stanislavov 2003 erectile function trial (Pycnogenol + L-arginine produced 80%+ ED-improvement rates that neither alone matched, because L-arginine provides the substrate and Pycnogenol upregulates the enzyme). Mechanism plausibility for Dylan: not currently needed, but layered cardiovascular insurance and theoretical pump / vascular reactivity benefit during MMA conditioning.

3. Mild platelet aggregation inhibition. Pycnogenol reduces thromboxane B2 (TXB2) production and ADP- / collagen-induced platelet aggregation modestly. The clinical signal is real (smoker-induced platelet aggregation reduced in human trials; minor reduction in DVT incidence in long-haul flight RCTs at 100-200 mg/day) but the magnitude is much smaller than aspirin or P2Y12 inhibitors. Practical implication: theoretical additive bleeding risk with aspirin / NSAIDs / DOACs at high doses; not enough to be clinically alarming for Dylan but worth flagging for athletes on chronic NSAID use or pre-surgical patients.

4. NF-κB / COX-2 / 5-LOX downregulation. Like curcumin (different mechanism — direct binding rather than IKK inhibition), Pycnogenol attenuates NF-κB nuclear translocation in monocytes and reduces COX-2, iNOS, IL-1β, IL-6, TNF-α expression. Also inhibits 5-lipoxygenase, reducing leukotriene-driven inflammation — relevant for the allergic rhinitis trials (Wilson 2010, Belcaro 2014) where Pycnogenol started 5-8 weeks before pollen season measurably reduced symptom scores.

5. Collagen + elastin binding (vascular wall + skin matrix protection). OPCs have high binding affinity for collagen and elastin, where they (a) protect the proteins from elastase / collagenase degradation, (b) cross-link partially, increasing matrix stability, and (c) reduce capillary fragility. This mechanism underlies the chronic venous insufficiency and capillary fragility signals (Cochrane review supports CVI symptom improvement) and the modest skin-elasticity / hydration trials. Possibly relevant for Dylan over decades (vascular wall preservation, skin aging) but not for acute training adaptations.

6. Glucose disposal + insulin sensitivity. Pycnogenol inhibits intestinal alpha-glucosidase (slowing carbohydrate absorption — similar magnitude to a low-dose acarbose), reduces post-prandial glucose excursions in T2D RCTs (Liu 2004, Zibadi 2008), and at chronic dosing improves HbA1c modestly (~0.3-0.5 percentage points in T2D meta-analyses). Mechanism: combination of alpha-glucosidase inhibition + endothelial NO improvement (improves insulin delivery to muscle) + Nrf2-adjacent antioxidant defense (reduces glucotoxicity-driven beta-cell stress). Not relevant to Dylan acutely but useful context for the longevity / metabolic-insurance frame.

7. Mild estrogen receptor modulation + testosterone preservation. Some preclinical data shows Pycnogenol acts as a weak SERM-like compound (mixed agonist / antagonist depending on tissue and estrogen background); human data is thin and mostly negative for hormonal disruption. The Stanislavov 2003 ED trial reported small testosterone increases with Pycnogenol + L-arginine, but the design wasn't isolated to test that endpoint. Net: no concerning hormonal signal at supplement doses.

8. Anti-platelet / pro-fibrinolytic during long-haul flights. Multiple Belcaro RCTs (2004, 2005) showed Pycnogenol 100-200 mg taken before and during long flights significantly reduced DVT and superficial vein thrombosis incidence — the mechanism is the antiplatelet + endothelial NO + capillary protection combination. Niche use case but well-replicated.

9. ADHD adjunct mechanism — speculative. The Trebatická 2006 Slovakia RCT (n=61 children, Pycnogenol 1 mg/kg/day vs placebo, 4 weeks) showed significant reduction in attention deficit and hyperactivity scores on Conners' rating scales. Mechanism hypothesized: catecholamine modulation (urinary catecholamine metabolites changed in active arm), antioxidant defense (oxidative stress is elevated in ADHD), and possibly endothelial / cerebral perfusion improvement. Replication is mixed (Parveen 2017 small Indian RCT positive; Verlaet 2017-2018 Belgian RCTs more equivocal). Real signal but smaller and less consistent than stimulants — useful as adjunct, not replacement.

10. Cognitive function in older adults — modest. Belcaro 2008 and Ryan 2008 trials in older adults (n=87, n=60, Pycnogenol 100-150 mg/day, 12 weeks) showed modest improvements in working memory, attention, and decision speed. Mechanism plausibly cerebral perfusion + endothelial NO + antioxidant defense. Effect size is small-to-moderate; younger adults haven't been studied as cleanly.